Esperion Therapeutics
$38.629876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$38.62
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.62 (1.63%) Today
$0.00 (0.00%) As of 4:07 PM EDT after-hours
Why Robinhood?
You can buy or sell ESPR and other stocks, options, ETFs, and crypto commission-free!
About ESPR
Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. Read More The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Employees
76
Headquarters
Ann Arbor, Michigan
Founded
1998
Market Cap
1.05B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
470.31K
High Today
$38.74
Low Today
$37.45
Open Price
$38.33
Volume
478.54K
52 Week High
$60.99
52 Week Low
$36.06
Collections
Price Paid on Robinhood
20% Lower
Right Now
52 Week Low
$33.06
Average Price Paid
$48.26
52 Week High
$73.33
Analyst Ratings
83%
of 12 ratings
Buy
83%
Hold
8%
Sell
8%
ESPR Earnings
-$2.24
-$0.47
$1.30
$3.07
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$1.86 per share
Actual
-$2.01 per share